13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

  
6 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2005-001340-22-CZ
(EUCTR)		09/04/200630/08/2005BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSISBHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).Product Name: BHT-3009
Product Code: BHT-3009		Bayhill TherapeuticsNULLNot RecruitingFemale: yes
Male: yes		252Finland;United Kingdom;Czech Republic
2NCT00382629
(ClinicalTrials.gov)		February 200627/9/2006BHT-3009 Immunotherapy in Relapsing Remitting Multiple SclerosisBHT-3009 Immunotherapy in Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: BHT-3009 0.5 mg;Drug: BHT-3009 1.5 mg;Drug: PlaceboBayhill TherapeuticsNULLCompleted18 Years55 YearsBoth252Phase 2NULL
3EUCTR2005-001340-22-FI
(EUCTR)		29/11/200522/07/2005BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSISBHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).Product Name: BHT-3009
Product Code: BHT-3009		Bayhill TherapeuticsNULLNot RecruitingFemale: yes
Male: yes		252Finland;Czech Republic;United Kingdom
4EUCTR2005-001340-22-SK
(EUCTR)		27/09/200529/07/2005BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSISBHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).Product Name: BHT-3009
Product Code: BHT-3009		Bayhill TherapeuticsNULLNot RecruitingFemale: yes
Male: yes		252Phase 2Czech Republic;Slovakia;Finland;United Kingdom
5EUCTR2005-001340-22-GB
(EUCTR)		12/08/200518/07/2005BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSISBHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).Product Name: BHT-3009
Product Code: BHT-3009		Bayhill TherapeuticsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		252Finland;Czech Republic;United Kingdom
6NCT00103974
(ClinicalTrials.gov)		July 200417/2/2005Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple SclerosisA Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple SclerosisMultiple SclerosisBiological: BHT-3009-01Bayhill TherapeuticsNULLCompleted18 Years65 YearsBoth30Phase 1United States;Canada

Back to top